

# Novel therapy for IBD

Biotech and Health Care

- Rectal therapy with compound X – an investment opportunity

## Effects on pathophysiology




Figure 1. Rectal compound X treatment reduces weight loss and improves weight gain during AOM+DSS colitis. The murine colitis index is also improved by the treatment

## Effects on biomarkers




Figure 2. Rectal compound X treatment reduces the expression of a well known inflammatory marker in the colon

## Effect on molecular target




Figure 3. Rectal compound X treatment increases the expression of a potential molecular anti-inflammatory mediator in the colon

## Proposed mechanism of action




Figure 4. proposed mechanism of action for Compound X as compared with current therapies

### Key selling points

We have invented a novel therapeutic principle for treatment of inflammatory bowel disease and the therapy is especially well suited for the treatment of ulcerative colitis. The current state-of-the-art therapy for IBD targets the immune system and involves the uses of 5-aminosalicylates, steroids, thiopurines and biological therapies such as e.g. anti-tumor necrosis factor alpha antibodies.

The unique properties of the therapy are:

- Based on the repurposing of a known substance – compound X
- Targeting the epithelium rather than the immune system
- Anti-tumorigenic effect in the colon

### Business Opportunity/commercial perspectives

We seek investors to enter the pre-seed / seed phase following the planned human pilot study. With rectal compound X therapy our first priority is ulcerative colitis with limited extension with an estimated world-wide annual market of 1.7 billion USD. It is envisioned that rectal compound X therapy can reach an initial 2% of the market for treatment of ulcerative colitis, rising to 20% within five years of marketing.

### Technology description

Compound X is instilled rectally in a volume of 100-200 ml of phosphate buffered saline. The volume may be increased in order to increase the mucosal area covered. Compound X is administered daily during active disease by the patients themselves at home. The rectal administration is already used for the drugs most frequently used in IBD (steroids and 5-aminosalicylates) and is well tolerated by the patients. Compound X may also be used in combination with existing IBD therapies.

### Development phase

Based on a solid basis of experimental evidence from experiments in the murine azoxymethane (AOM) + dextran sulphate sodium (DSS) model for inflammation and inflammation induced colorectal cancer, we are currently taking the project into a human pilot study.

### The inventors

Prof. DMSc, MD, Jørgen Olsen  
Ph.D. MS. Mohammad Yassin  
DMSc, MD, Anders Elm Pedersen

### Contact information

Peter Stein Nielsen  
Commercial Officer  
[peter.nielsen@adm.ku.dk](mailto:peter.nielsen@adm.ku.dk)  
+45 2164 7447

Intellectual property rights: EP priority patent application filed on November 14, 2016